{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:24:28Z","timestamp":1740108268700,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EMS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction and hypothesis<\/jats:title>\n                <jats:p>Dysuria is a common symptom present in several urological and gynecological conditions. Management relies on the underlying disease but may require additional symptomatic treatment. This study evaluated the combination of methenamine 250\u00a0mg and methylthioninium chloride 20\u00a0mg in the treatment of dysuria versus phenazopyridine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a multicenter, single-blind, randomized, superiority clinical trial, including individuals over 18 with dysuria and a score\u2009\u2265\u20095 points on the pre-treatment categorical scale for pain. The primary outcome was the proportion of participants presenting excellent clinical response within 24\u00a0h after treatment. Improvement up to 72\u00a0h, time to reach improvement, sustained healing, investigators\u2019 opinion, and safety were also evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three hundred and fifteen participants were evaluated. Demographic characteristics and symptoms of dysuria were comparable between groups at baseline. The difference in the excellent response rate between treatments within 24\u00a0h was 12.7% (95% CI 6.16, 19.21) for pain, 9.4% (95% CI 3.32, 15.39) for burning, and 12.7% (95% CI 6.37, 18.99) for burning on urination, all in favor of the test drug, which was also superior from 36 to 48\u00a0h. Treatments were similar concerning time to reach the absence of symptoms and in the percentage of participants with sustained healing after 72\u00a0h.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The association of methenamine with methylthioninium is superior to phenazopyridine in the treatment of dysuria.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00192-023-05669-0","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T10:02:01Z","timestamp":1697623321000},"page":"3051-3058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of methenamine with methylthioninium in the treatment of dysuria: a randomized clinical study"],"prefix":"10.1007","volume":"34","author":[{"given":"Fel\u00edcio Savioli","family":"Neto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Hachul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rcio Ant\u00f4nio","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-4222","authenticated-orcid":false,"given":"Carlos Isaia","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"5669_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mcna.2010.08.025","volume":"95","author":"ML Guralnick","year":"2011","unstructured":"Guralnick ML, O\u2019Connor RC, See WA. Assessment and management of irritative voiding symptoms. Med Clin North Am. 2011;95:121\u20137.","journal-title":"Med Clin North Am"},{"key":"5669_CR2","unstructured":"Mehta P, Leslie SW, Reddivari AKR. Dysuria. StatPearls. 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549918\/. Accessed 15 Mar 2023."},{"key":"5669_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1464-410X.2009.08427.x","volume":"104","author":"KS Coyne","year":"2009","unstructured":"Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352\u201360.","journal-title":"BJU Int"},{"key":"5669_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","volume":"28","author":"B Foxman","year":"2014","unstructured":"Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1\u201313.","journal-title":"Infect Dis Clin North Am"},{"key":"5669_CR5","first-page":"603","volume":"54","author":"JCL Arroyo","year":"2020","unstructured":"Arroyo JCL, Moraes RO, Silva EF, S\u00e1 OR, Fran\u00e7a N. Preval\u00eancia de infec\u00e7\u00e3o do trato urin\u00e1rio entre pacientes atendidos na Unidade de Pronto Atendimento (UPA) no munic\u00edpio de Passos \u2013 MG [Prevalence of Urinary Tract Infection Among Patients Attended at the Emergency Care Unit (ECU) at the Municipality of Passos \u2013 MG]. Rev Mult Psic. 2020;54:603\u201316.","journal-title":"Rev Mult Psic"},{"issue":"2","key":"5669_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/emp2.12694","volume":"3","author":"MD Zilberberg","year":"2022","unstructured":"Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016\u20132018. J Am Coll Emerg Physicians Open. 2022;3(2): e12694.","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"5669_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1586\/eri.12.72","volume":"10","author":"V Pergialiotis","year":"2012","unstructured":"Pergialiotis V, Arnos P, Mavros MN, Pitsouni E, Athanasiou S, Falagas ME. Urinary tract analgesics for the treatment of patients with acute cystitis: where is the clinical evidence? Expert Rev Anti Infect Ther. 2012;10:875\u20139.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5669_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-0068229","volume":"376","author":"C Harding","year":"2022","unstructured":"Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022;376: e068229.","journal-title":"BMJ"},{"key":"5669_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00192-021-04849-0","volume":"33","author":"C Botros","year":"2022","unstructured":"Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J. 2022;33:571\u201380.","journal-title":"Int Urogynecol J"},{"key":"5669_CR10","doi-asserted-by":"publisher","first-page":"2325.e7","DOI":"10.1016\/j.neurobiolaging.2010.12.012","volume":"32","author":"RH Schirmer","year":"2011","unstructured":"Schirmer RH, Adler H, Pickhardt M, Mandelkow E. Lest we forget you\u2013methylene blue. Neurobiol Aging. 2011;32:2325.e7\u201316.","journal-title":"Neurobiol Aging"},{"key":"5669_CR11","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"key":"5669_CR12","first-page":"224","volume":"3","author":"C Deepalatha","year":"2011","unstructured":"Deepalatha C, Deshpande N. A comparative study of phenazopyridine (pyridium) and cystone as short-term analgesic in uncomplicated urinary tract infection. Int J Pharm Pharm Sci. 2011;3:224\u20136.","journal-title":"Int J Pharm Pharm Sci"},{"key":"5669_CR13","first-page":"441","volume":"12","author":"PC Trickett","year":"1970","unstructured":"Trickett PC. Ancillary use of phenazopyridine (Pyridium) in urinary tract infections. Curr Ther Res Clin Exp. 1970;12:441\u20135.","journal-title":"Curr Ther Res Clin Exp"},{"key":"5669_CR14","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/0090-4295(75)90111-9","volume":"5","author":"S Gould","year":"1975","unstructured":"Gould S. Urinary tract disorders. Clinical comparison of flavoxate and phenazopyridine. Urology. 1975;5:612\u20135.","journal-title":"Urology"},{"key":"5669_CR15","first-page":"729","volume":"52","author":"TCM Christiaens","year":"2002","unstructured":"Christiaens TCM, Meyere MD, Verschraegen G, Peersman W, Heytens S, Maeseneer JM. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract. 2002;52:729\u201334.","journal-title":"Br J Gen Pract"},{"key":"5669_CR16","first-page":"CD003265","volume":"10","author":"BS Lee","year":"2012","unstructured":"Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD003265.","journal-title":"Cochrane Database Syst Rev"},{"key":"5669_CR17","first-page":"367","volume":"65","author":"M Geller","year":"2008","unstructured":"Geller M, Gama CRB, Guimar\u00e3es OR, et al. Recurrent urinary tract infections: evaluation of the prophylactic efficacy of urinary antiseptics methenamine and methylthioninium chloride. RBM Rev Bras Med. 2008;65:367\u201371.","journal-title":"RBM Rev Bras Med"},{"key":"5669_CR18","first-page":"639","volume":"12","author":"CRB Gama","year":"2020","unstructured":"Gama CRB, Pombo MAG, Nunes CP, et al. Treatment of recurrent urinary tract infection symptoms with urinary antiseptics containing methenamine and methylene blue: analysis of etiology and treatment outcomes. Res Rep Urol. 2020;12:639\u201349.","journal-title":"Res Rep Urol"},{"key":"5669_CR19","unstructured":"Eastham JH, Patel P. Phenazopyridine. StatPearls. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK580545\/. Accessed 6 Apr 2023."},{"key":"5669_CR20","first-page":"439","volume":"18","author":"K Kamali","year":"2020","unstructured":"Kamali K, Nikbakht J, Ayubi E, Nabizadeh M, Sarhadi S. Comparison of the efficacy of oxybutynin, phenazopyridine, celecoxib, and placebo in the treatment of urinary tract symptoms after BCG therapy in patients with bladder tumors. Urol J. 2020;18:439\u201344.","journal-title":"Urol J"},{"key":"5669_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1586\/14787210.2014.904202","volume":"12","author":"TS Lo","year":"2014","unstructured":"Lo TS, Hammer KD, Zegarra M, Cho WC. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Rev Anti Infect Ther. 2014;12:549\u201354.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5669_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1472-765X.2010.02825.x","volume":"50","author":"M Wainwright","year":"2010","unstructured":"Wainwright M, Stanforth A, Jones R, Loughran C, Meegan K. Photoantimicrobials as a potential local approach to geriatric UTIs. Lett Appl Microbiol. 2010;50:486\u201392.","journal-title":"Lett Appl Microbiol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05669-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-023-05669-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05669-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T13:04:31Z","timestamp":1703855071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-023-05669-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5669"],"URL":"https:\/\/doi.org\/10.1007\/s00192-023-05669-0","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"type":"print","value":"0937-3462"},{"type":"electronic","value":"1433-3023"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors were principal investigators of their respective research centers and received a fee for including patients in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}